文献速递脑血管病

芬戈莫德在昼夜节律活跃期或非活跃期均不减少小鼠局灶性脑缺血后的梗死

Fingolimod Does Not Reduce Infarction After Focal Cerebral Ischemia in Mice During Active or Inactive Circadian Phases.
PubMed 文献 · Stroke · 2022-10-12

该研究在小鼠短暂性和永久性大脑中动脉闭塞模型中,于昼夜节律非活跃期或活跃期给予芬戈莫德1 mg/kg,评估梗死体积、脑肿胀、出血转化和行为结局。结果显示芬戈莫德虽降低外周淋巴细胞数,但未显著改善上述结局;作者认为除非转化研究能识别与芬戈莫德疗效或缺乏疗效相关的因素,否则可能不支持进一步临床试验。

要点

  • 芬戈莫德1 mg/kg在短暂性或永久性局灶性脑缺血小鼠中未显著减少梗死体积。
  • 芬戈莫德未显著改善脑肿胀、出血转化或行为结局。
  • 无论缺血发生于昼夜节律非活跃期还是活跃期,芬戈莫德均未改善结局。

核心结论

  • 在短暂性和永久性局灶性脑缺血中,无论昼夜节律活跃期还是非活跃期,芬戈莫德均未改善结局。
  • 这些阴性结果提示,除非转化研究能识别与芬戈莫德疗效或缺乏疗效相关的因素,否则可能不支持进一步临床试验。

研究设计与样本

  • 在雄性C57Bl/6小鼠中实施两种卒中模型:短暂性大脑中动脉闭塞和永久性远端大脑中动脉闭塞。
  • 闭塞在昼夜节律非活跃期或活跃期进行。
  • 永久性和短暂性大脑中动脉闭塞分别于闭塞后30分钟或60分钟给予1 mg/kg芬戈莫德,并于1天后再次给药。
  • 在卒中后2天或3天评估梗死体积、脑肿胀、出血转化和行为结局。
  • 在2个不同实验室进行了三项独立实验。

主要发现

  • 芬戈莫德如预期降低了幼稚小鼠的外周淋巴细胞数。
  • 在短暂性或永久性局灶性脑缺血后2天或3天,芬戈莫德未显著影响梗死体积、脑肿胀、出血转化或行为结局。
  • 在卒中发病的昼夜节律非活跃期或活跃期,芬戈莫德均未显著影响上述结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been reported that the S1P (sphingosine 1-phosphate) receptor modulator fingolimod reduces infarction in rodent models of stroke. Recent studies have suggested that circadian rhythms affect stroke and neuroprotection. Therefore, this study revisited the use of fingolimod in mouse focal cerebral ischemia to test the hypothesis that efficacy might depend on whether experiments were performed during the inactive sleep or active wake phases of the circadian cycle. METHODS: Two different stroke models were implemented in male C57Bl/6 mice-transient middle cerebral artery occlusion and permanent distal middle cerebral artery occlusion. Occlusion occurred either during inactive or active circadian phases. Mice were treated with 1 mg/kg fingolimod at 30- or 60-minute postocclusion and 1 day later for permanent and transient middle cerebral artery occlusion, respectively. Infarct volume, brain swelling, hemorrhagic transformation, and behavioral outcome were assessed at 2 or 3 days poststroke. Three independent experiments were performed in 2 different laboratories. RESULTS: Fingolimod decreased peripheral lymphocyte number in naive mice, as expected. However, it did not significantly affect infarct volume, brain swelling, hemorrhagic transformation, or behavioral outcome at 2 or 3 days after transient or permanent focal cerebral ischemia during inactive or active circadian phases of stroke onset. CONCLUSIONS: Outcomes were not improved by fingolimod in either transient or permanent focal cerebral ischemia during both active and inactive circadian phases. These negative findings suggest that further testing of fingolimod in clinical trials may not be warranted unless translational studies can identify factors associated with fingolimod's efficacy or lack thereof.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mandeville ET, Li W, Quinto-Alemany D, et al. Fingolimod Does Not Reduce Infarction After Focal Cerebral Ischemia in Mice During Active or Inactive Circadian Phases. Stroke. 2022. PMID: 36252110. doi:10.1161/STROKEAHA.122.039932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。